Aurora Cannabis Inc.（ACB）資訊與事件ACBAurora Cannabis Inc.

Aurora Cannabis Recommends Shareholders Reject Curaleaf's Acquisition Offer

Aurora Cannabis (ACB) reconfirms that its board, on the unanimous recommendation of a special committee of independent directors, unanimously recommends that shareholders reject the "hostile offer" by Curaleaf (CURLF) for all of the issued and outstanding common shares of the company. "Curaleaf's revised offer still does not reflect the value of the company Aurora shareholders own today. Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount," said Miguel Martin, CEO of Aurora.

Aurora Cannabis Explores Alternatives to Surpass Curaleaf's Acquisition Bid

Aurora Cannabis (ACB) said that its special committee, with the assistance of its advisors, is actively exploring a range of alternatives that may offer shareholders greater value than Curaleaf's (CURLF) revised "hostile bid." These alternatives include a possible transaction with one or more third parties or remaining independent and pursuing Aurora's existing strategy as a stand-alone entity, the company said in a statement. The special committee has solicited a number of parties to ascertain their interest in Aurora. Aurora has entered into confidentiality and standstill agreements with multiple parties, each of whom have been examining information relating to Aurora, the company added. It said, "Aurora has had numerous discussions with these parties. As this process is ongoing, it is not possible at this time to predict with certainty what alternatives (if any) may emerge from this process. There can be no assurance that the process will result in a transaction. However, shareholders should not tender their shares until the process is completed."

Aurora Cannabis Completes Facility Expansion in Leuna, Germany

Aurora Cannabis announced the completion of an expansion of its facility in Leuna, Germany. The expansion project incorporates cultivation and post-harvest practices from Aurora's Canadian operations alongside the company's proprietary genetics and product catalogue. The expanded facility has increased cultivation capacity. The expanded facility has recently been granted an expanded EU-GMP license for the newly built areas of the site, issued by the State Office for Social Affairs, Youth and Health of Saxony-Anhalt. The additional capacity is expected to help Aurora meet demand for medical cannabis in Germany and across European markets.